Development and Production Activities Sample Clauses

Development and Production Activities. The CRMC’s CZMA six-month review period for the Revolution Wind project began on August 6, 2021.2 The CRMC issued its 3-month letter to Revolution Wind on October 21, 2021 pursuant to the requirements of 15 C.F.R. § 930.78(a). In that letter the CRMC detailed specific information requirements that Revolution Wind has been requested to provide to the CRMC in order to complete the CRMC’s federal consistency review pursuant to its enforceable policies. 1 Revolution Wind, LLC is a50/50 joint venture between Ørsted and Eversource Investment LLC. 2 The CRMC notified BOEM and Revolution Wind in a letter dated August 18, 2021 that commencement of the CRMC CZMA consistency review for the Revolution Wind project began on August 6, 2021. Revolution Wind wants to confer with CRMC about the information that it seeks in the 3-month letter issued pursuant to 15 C.F.R. § 930.78(a). Revolution Wind identifies within its COP at Section 1.4.1.2 that the CRMC federal consistency decision for the project is anticipated between Q1 and Q3 2023. In addition, BOEM issued its Notice of Availability for the Draft Environmental Impact Statement (XXXX) in September 2022, and there is considerable information that CRMC believes is valuable to CRMC’s decision making process within the XXXX, including the range of expected project alternatives and mitigation measures.3 Furthermore, the Revolution Wind project has undergone significant refinement in recent months which require substantial State agency time and resources to analyze. In accordance with 15 CFR § 930.60(b), and in consideration of the parties’ mutual interest that the State have additional time to fully assess the proposed project’s consistency with the State’s enforceable policies, the CRMC and Revolution Wind mutually agree to the following dates and to stay the CRMC CZMA six-month review period as specified herein.
Sample 1
AutoNDA by SimpleDocs
Development and Production Activities. During the Option Period, Purchaser shall have the right to engage in development and pre-production activities with respect to the Property and the Project. Any and all material created or written in connection with such development or pre-production activity shall remain Purchaser’s sole and exclusive property (whether or not Purchaser exercises the Option). Upon expiration of the Option, all rights to all materials created in connection with the Property, including, without limitation, the results and proceeds of all writing services rendered by Seller or by or for Purchaser and its employees and agents, shall revert or will be assigned free and clear to Seller.
Sample 1
Development and Production Activities. XXXX announced in August 2019 that it would expand the cumulative impact analysis of offshore wind energy projects within its draft Environmental Impact Statement (EIS) for the Vineyard Wind project (Docket No. BOEM-2020-0005). XXXX released the supplemental Draft 1 Deepwater Wind South Fork, LLC (DWSF) is a subsidiary of Ørsted U.S. Offshore Wind. The South Fork Wind Farm project is a 50/50 joint venture between Ørsted and Eversource. 2 In January 2020, Deepwater Wind New England, LLC requested that BOEM assign a portion of Lease Area OCS-A 0486 to DWSF. XXXX approved the assignment on March 23, 2020 with the new lease number OCS-A 0517. CRMC-Deepwater Wind 4th Amended Stay Agreement 1 of 3 EIS for the Vineyard Wind project on June 12, 2020 and has previously indicated that the cumulative impact analysis methodology will be applied to all other pending and future offshore wind energy projects, which includes the SWF project. Since BOEM’s August 2019 announcement concerning the Vineyard Wind project, federal review of other offshore wind energy projects has been paused. On February 13, 2020 Xxxxxx filed with BOEM a revised Construction and Operation Plan. XXXX, however, has yet to remove the federal review pause for the SWF project. In addition, Xxxxxx will be providing the CRMC with additional submissions for consideration by the CRMC pursuant to its enforceable policies. Thus, additional review time is warranted to achieve development of a mitigation plan and subsequent negotiations as required under the CRMC’s enforceable policies. In accordance with 15 CFR § 930.60(b), and in consideration of the parties’ mutual interest that the State have additional time to fully assess the proposed project’s consistency with the State’s enforceable policies, the CRMC and Deepwater Wind mutually agree to the following dates and to stay the CRMC CZMA six-month review period as specified herein. • Date the CRMC 6-month review period commenced: October 22, 2018 • Date the 6-month review period was to end: August 31, 2020 • Date during the 6-month review period that the stay begins: June 22, 2020 • Date that the stay ends: November 23, 2020 (70 days remaining in the 6-month review period) • Date the 6-month review period ends and the CRMC consistency decision is due: January 31, 2021 The CRMC will issue its consistency decision on or before January 31, 2021 unless Deepwater Wind and CRMC mutually agree in writing to another later date. Furthermore, should the CRMC conclu...
Sample 1
Development and Production Activities 
Sample 1Sample 2Sample 3

Related to Development and Production Activities

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards the next clinical Development milestone or approval milestone, as described in Sections 7.4.2 or 7.4.3, respectively. If Novartis (itself or through its Affiliates or sublicensees) fails to dedicate commercially reasonable efforts, during any [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards such next milestone, then any dispute regarding Novartis’ failure of development diligence with respect to such Profile shall be resolved in accordance with Article 13.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!